55583-08-9 Usage
Uses
Used in Pharmaceutical Industry:
(1S)-1,4-anhydro-1-(2,4-dihydroxyphenyl)-D-ribitol is used as a medicinal compound for its potential antioxidant and anti-inflammatory properties, which can help in the treatment of various health conditions.
Used in Traditional Medicine:
(1S)-1,4-anhydro-1-(2,4-dihydroxyphenyl)-D-ribitol is used as a natural remedy for its potential to treat various health conditions, based on its presence in certain plants and its traditional use.
Used in Antimicrobial Applications:
(1S)-1,4-anhydro-1-(2,4-dihydroxyphenyl)-D-ribitol is used as an antimicrobial agent for its potential role in inhibiting the growth of certain pathogenic bacteria, contributing to the development of new treatments for bacterial infections.
Check Digit Verification of cas no
The CAS Registry Mumber 55583-08-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,5,8 and 3 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 55583-08:
(7*5)+(6*5)+(5*5)+(4*8)+(3*3)+(2*0)+(1*8)=139
139 % 10 = 9
So 55583-08-9 is a valid CAS Registry Number.
55583-08-9Relevant academic research and scientific papers
Base- and sugar-modified cytidine monophosphate N-acetylneuraminic acid (CMP-Neu5Ac) analogues - Synthesis and studies with α(2-6)-sialyltransferase from rat liver
Dufner, Gesche,Schwoerer, Ralf,Mueller, Bernd,Schmidt, Richard R.
, p. 1467 - 1482 (2007/10/03)
The reaction of sialyl phosphites 1, 22a-d, 28, 39, and 45 with acyl- protected riboside 5-phosphorous acids 2a,b and 23 directly furnished, without addition of a catalyst, under phosphite/phosphate exchange the corresponding β-configured sialyl riboside monophosphates 3a,b, 24a-d, 29, 46, and 47. The synthesis of the starting materials, formation of the products, and their treatment with sodium methanolate in methanol and subsequent hydrolysis of the sialic acid ester moiety to provide the unprotected target molecules 4a,b, 25a-d, 30, 48, and 49 is described. Investigations with α(2-6)-sialyltransferase from rat liver showed that base replacement in CMP-Neu5Ac (4a,b) is not tolerated by the enzyme but that modifications of the 5-, 8-, or 9-position of the neuraminic acid residue (25a-d, 30, 48, 49) are tolerated.
